Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.79 USD
Change Today -0.08 / -4.28%
Volume 773.3K
ATRS On Other Exchanges
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $3.04
52 Week Low
08/24/15 - $1.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Vibex self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle. Its transdermal gel products comprise Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company also offers OTREXUP, an injection for subcutaneous use indicated for adults with severe active RA, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis, as well as Vibex auto injectors. In addition, it is developing Vibex QS T for testosterone replacement therapy for men who have testosterone deficiency; Vibex QS M with an undisclosed drug for treatment of a CNS indication; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Meda Pharmaceuticals, Inc.; Pfizer Inc; Population Council; and LEO Pharma, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

93 Employees
Last Reported Date: 03/12/15
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $292.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $43.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $391.1K
Compensation as of Fiscal Year 2014.

antares pharma inc (ATRS) Key Developments

Antares Pharma Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Antares Pharma Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $14.4 million, compared to $6.3 million for the comparable period in 2014, representing an increase of 128%. Net loss was approximately $1.5 million compared to $9.1 million for the same period a year ago. Operating loss was $1,462,000 compared to $9,091,000 for the same period a year ago. Basic and diluted net loss per common share was $0.01 compared to $0.07 a year ago. For the six months ended June 30, 2015, the company’s total revenue was $22.8 million, a 97% increase as compared to the total revenue of $11.5 million for the six months ended June 30, 2014. Net loss was approximately $8.3 million compared to $17.9 million for the comparable periods in 2014. Operating loss was $8,203,000 compared to $17,899,000 a year ago. Basic and diluted net loss per common share was $0.06 compared to $0.14 a year ago.

Antares Pharma Announces First Patients Enrolled in QuickShot® Testosterone Supplemental Safety Study

Antares Pharma Inc. announced that the first patients have been enrolled in a double-blind, multiple-dose, 26-week safety and pharmacokinetic study of QuickShot® Testosterone (QS T) administered subcutaneously once each week to adult males with hypogonadism. The study will include a screening phase, a treatment titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. Approximately 70 patients will be needed to complete collection of 26 weeks of safety data. Patients meeting all eligibility criteria will be assigned to receive 75 mg of QS T once weekly for six weeks. Adjustments to dose may be made at week seven based upon the week six Ctrough value. QS T will be provided to clinical sites at dosage strengths of 100 mg, 75 mg and 50 mg to be utilized in dose titration.

Antares Pharma Inc. to Report Q2, 2015 Results on Aug 10, 2015

Antares Pharma Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 10, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $1.79 USD -0.08

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioject Medical Technologies Inc $0.05 USD -0.003
Hospira Inc $89.95 USD 0.00
Mylan NV $47.42 USD -1.20
West Pharmaceutical Services Inc $55.34 USD -0.31
Ypsomed Holding AG SFr.105.00 CHF 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at